- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Glenmark Pharmaceuticals Limited — Board Meeting, 29-05-2026: Outcome of Board Meeting
29-05-2026 | 08:16 pm
29-05-2026 | 08:16 pm
Glenmark Pharma's board approved its Q4 & FY26 consolidated financial results. Full-year revenue reached ₹16,982.51 Cr. Net profit stood at ₹1,361.85 Cr, impacted by significant one-off charges. A final dividend of ₹2.50 per share was declared.
No comments yet. Be the first to comment!